Efficacy of calcium carbonate and low-dose vitamin D/1,25(OH)2D3 in reducing the risk of developing renal osteodystrophy in children on continuous ambulatory peritoneal dialysis.
Eight children with terminal renal insufficiency on continuous ambulatory peritoneal dialysis were followed for 12 months to evaluate laboratory parameters of mineral ion and bone metabolism. Calcium carbonate (range 47-295 mg/kg body weight per day) was given in combination with low doses of either vitamin D or 1,25(OH2D3. Blood urea nitrogen and serum phosphate concentrations remained well controlled throughout the observation period. A significant increase in serum calcium levels from 2.35 +/- 0.18 to 2.61 +/- 0.22 mmol/l (mean +/- SD) was observed during the first 6 months. Alkaline phosphatase activity and mid-C-regional parathyroid hormone, both indirect parameters of bone metabolism, revealed no evidence of severe secondary hyperparathyroidism. Our data indicate that calcium carbonate may be sufficient to induce relative hypercalcaemia in uraemic children, and thus reduce the risk of developing renal osteodystrophy. Unwanted side-effects of vitamin D preparations, i.e. increased intestinal phosphate absorption and hypercalcaemia after successful renal transplantation, may thus be avoided.
Jüppner
H
H
Kinderklinik, Medizinische Hochschule Hannover, Federal Republic of Germany.
Hoyer
P F
PF
Latta
K
K
Winkler
L
L
Offner
G
G
Brodehl
J
J
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000469:Alkaline Phosphatase / Q000652:urine; D001806:Blood Urea Nitrogen; D001842:Bone and Bones / Q000378:metabolism; D002117:Calcitriol / Q000009:adverse effects / Q000627:therapeutic use*; D002119:Calcium Carbonate / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D006934:Hypercalcemia / Q000517:prevention & control; D007223:Infant; D010280:Parathyroid Glands / Q000187:drug effects; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D014807:Vitamin D / Q000009:adverse effects / Q000627:therapeutic use*; D014882:Water-Electrolyte Balance / Q000187:drug effects
D014807:Vitamin D; D000469:Alkaline Phosphatase; D002117:Calcitriol; D002119:Calcium Carbonate